Status:
UNKNOWN
Bakri Balloon Plus Tranexamic Acid During Cesarean Delivery for Placenta Previa
Lead Sponsor:
Aswan University Hospital
Conditions:
Placenta Previa
Eligibility:
FEMALE
18-45 years
Phase:
NA
Brief Summary
Objective to investigate the effect of adjunctive intravenous tranexamic acid (TA) on blood loss during cesarean section (CS) in patients with placenta previa undergone Bakri balloon tamponade
Detailed Description
Placenta previa (PP) is an obstetric condition that is closely linked with massive obstetric hemorrhage with a varied incidence about once in every 200 live births. It is considered one of the causes ...
Eligibility Criteria
Inclusion
- women undergoing elective cesarean delivery for complete placenta previa which not respond uterotonic and simple hemostatic maneuvers like placental bed hemostatic sutures
Exclusion
- patients with the high possibility of morbid adherent placenta
- those presented with severe antepartum hemorrhage
- Patients with cardiac, hepatic, renal, or thromboembolic disease;
- hypersensitivity or contraindications of use of tranexamic acid
- patient refuses to consent
Key Trial Info
Start Date :
September 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 31 2022
Estimated Enrollment :
140 Patients enrolled
Trial Details
Trial ID
NCT04518163
Start Date
September 1 2020
End Date
July 31 2022
Last Update
September 21 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Aswan University Hospital
Aswān, Egypt, 81528